Compare Hut 8 Corp (HUT) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hut 8 Corp vs Novo Nordisk A/S — how do they compare? Hut 8 Corp trades at $84.13 (market cap $9.82B), while Novo Nordisk A/S trades at $38.62 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 16.8× Hut 8 Corp's market cap, and Novo Nordisk A/S pays a 4.71% dividend while Hut 8 Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hut 8 Corp for 11 Days and Novo Nordisk A/S for 116 Days on average.
| HUT | NVO | |
|---|---|---|
Market Cap | $9.82B | $165.31B |
Volume | 10,272,678 | 11,432,838 |
Sector | Financials | Health |
52-Week High | $133.02 | $63.98 |
52-Week Low | $33.76 | $35.29 |
Typical Hold Time | 11 Days | 116 Days |
Enterprise Value | $17.25B | $179.56B |
Dividend Yield | — | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HUT trades at $84.27, down 5.63% today, with a bearish technical outlook despite oversold RSI readings. The company reported negative earnings in recent quarters, missing expectations, with a net income margin of -188.59% for 2026. Recent positive developments include securing a $1.07 billion credit facility and analyst optimism around AI infrastructure contracts.
While analyst consensus is strongly bullish with a $162.69 price target, significant execution risks persist given negative profitability and cash flow challenges. The stock offers high potential upside if AI infrastructure contracts materialize but carries substantial risk from ongoing losses and competitive pressures in the digital infrastructure space.
Novo Nordisk (NVO) trades at $38.64, up 0.99% with bearish technical signals despite strong fundamentals. The company maintains exceptional profitability with 35.35% net margins and has beaten earnings estimates for three consecutive quarters. Recent news highlights pipeline developments including weight-loss drug advancements and a $4 billion licensing deal expansion.
While facing competitive pressure in obesity treatments, NVO's valuation remains attractive with a 9.66 P/E ratio. Analyst consensus is bullish with a $44.67 price target, representing 15.6% upside potential. Key risks include FDA regulatory delays and intensifying competition from Eli Lilly in the GLP-1 market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hut 8 Corp
Hut 8 is one of North America's largest digital asset miners and infrastructure providers. It operates diversified data centers supporting Bitcoin mining and high-performance computing (HPC) for AI.
Read more on HUT →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
